Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5751)
All Articles published online
|
Publishing Process of This Article
|
Oct 10, 2014 (publication date) through Apr 16, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014; 5(4): 560-567 [PMID: 25302160 DOI: 10.5306/wjco.v5.i4.560] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v5/i4/560.htm |
| Number | Citing Articles |
| 1 |
Yujia Shi, Zhengdao Mao, Yanhua Huang, Yun Sun, Qi Cao, Xiaowei Yin, Jianan Huang, Qian Zhang. Knockdown of HSDL2 inhibits lung adenocarcinoma progression via down-regulating AKT2 expression. Bioscience Reports 2020; 40(4) doi: 10.1042/BSR20200348
|
| 2 |
Anna Roth, Sven Diederichs. Long Non-coding RNAs in Human Disease. Current Topics in Microbiology and Immunology 2015; 394: 57 doi: 10.1007/82_2015_444
|
| 3 |
Giovanni Ribaudo, Enrico Zanforlin, Giuseppe Zagotto. Overcoming resistance in non‐small‐cell lung cancer: A practical lesson for the medicinal chemist. Archiv der Pharmazie 2018; 351(10) doi: 10.1002/ardp.201800037
|
| 4 |
Sivakumar Murugesan, Jayakumar Murugesan, Seedevi Palaniappan , Sivasankar Palaniappan, Tamilselvi Murugan, Shahid S. Siddiqui, Sivakumar Loganathan. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Current Cancer Drug Targets 2021; 21(1): 55 doi: 10.2174/1568009620666201009130008
|
| 5 |
Yan Lan, Shuo Zhou, Weihong Feng, Ying Qiao, Xueming Du, Fenge Li. Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. Clinics 2021; 76: e2251 doi: 10.6061/clinics/2021/e2251
|
| 6 |
Dao-Hong Chen, Xiao-Shi Zhang. Targeted therapy: resistance and re-sensitization. Chinese Journal of Cancer 2015; 34(3) doi: 10.1186/s40880-015-0047-1
|
| 7 |
Michael J. Grant, Katerina Politi, Scott Gettinger. Lung Cancer. Current Cancer Research 2021; : 75 doi: 10.1007/978-3-030-74028-3_5
|
| 8 |
Fenge Li, Ligang Deng, Kyle R Jackson, Amjad H Talukder, Arjun S Katailiha, Sherille D Bradley, Qingwei Zou, Caixia Chen, Chong Huo, Yulun Chiu, Matthew Stair, Weihong Feng, Aleksander Bagaev, Nikita Kotlov, Viktor Svekolkin, Ravshan Ataullakhanov, Natalia Miheecheva, Felix Frenkel, Yaling Wang, Minying Zhang, David Hawke, Ling Han, Shuo Zhou, Yan Zhang, Zhenglu Wang, William K Decker, Heather M Sonnemann, Jason Roszik, Marie-Andree Forget, Michael A Davies, Chantale Bernatchez, Cassian Yee, Roland Bassett, Patrick Hwu, Xueming Du, Gregory Lizee. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. Journal for ImmunoTherapy of Cancer 2021; 9(7): e002531 doi: 10.1136/jitc-2021-002531
|
| 9 |
Ying Jin, Yang Shao, Xun Shi, Guangyuan Lou, Yiping Zhang, Xue Wu, Xiaoling Tong, Xinmin Yu. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 2016; 7(38): 61755 doi: 10.18632/oncotarget.11237
|
| 10 |
Yuan Qin, Qiang Zhang, Shan Lee, Wei-long Zhong, Yan-rong Liu, Hui-juan Liu, Dong Zhao, Shuang Chen, Ting Xiao, Jing Meng, Xue-shuang Jing, Jing Wang, Bo Sun, Ting-ting Dai, Cheng Yang, Tao Sun, Hong-gang Zhou. Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget 2015; 6(38): 40667 doi: 10.18632/oncotarget.5842
|
| 11 |
SHENG-QI WANG, BO-XIN ZHAO, YUAN LIU, YA-TIAN WANG, QIAN-YING LIANG, YUN CAI, YUN-QI ZHANG, JIANG-HONG YANG, ZHI-HUA SONG, GUO-FENG LI. New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer. International Journal of Oncology 2016; 48(4): 1353 doi: 10.3892/ijo.2016.3375
|
| 12 |
William C. Eckelman, David A. Mankoff. Choosing a single target as a biomarker or therapeutic using radioactive probes. Nuclear Medicine and Biology 2015; 42(5): 421 doi: 10.1016/j.nucmedbio.2015.01.005
|
| 13 |
Dilip Narayanan, Osman A. B. S. M. Gani, Franz X. E. Gruber, Richard A. Engh. Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR. Journal of Cheminformatics 2017; 9(1) doi: 10.1186/s13321-017-0229-8
|